Imeglimin + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Jan 1, 2013 → Jul 1, 2014
NCT ID
NCT01951235About Imeglimin + Placebo
Imeglimin + Placebo is a phase 2 stage product being developed by Poxel for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT01951235. Target conditions include Type 2 Diabetes Mellitus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02373150 | Phase 1 | Completed |
| NCT01951235 | Phase 2 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus